About IPINOVYX BIO, INC.
IpiNovyx Bio is developing best-in-class proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases, leveraging cutting-edge research from Weill Cornell Medicine and the Hospital for Special Surgery.
Developing best-in-class proteasome inhibitorsCreating highly selective and reversible immunoproteasome inhibitorsAdvancing novel, reversible, and selective proteasome inhibitors for safer and more effective treatmentsPursuing clinical trials for lead program anticipated in 2026
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to IPINOVYX BIO, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.